Novo Nordisk (NYSE:NVO) rose to its highest level in over two months Monday after a media report said hedge fund Parvus Asset ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Novo Nordisk (NVO) shares hit their highest level in over two months following a Financial Times report that activist hedge ...

The London-based fund, which has targeted budget airline Ryanair and Italian bank UniCredit, wants to influence the ...

Hedge fund aims to influence CEO appointment as drugmaker battles share price slump and competition from Eli Lilly.

The U.S.-listed shares of Danish drugmaker Novo Nordisk rose Tuesday following a report that an activist investor is building ...

S&P 500, Eli Lilly and Company, Novo Nordisk A/S Class B, Novo Nordisk A/S. Read 's Market Analysis on Investing.com ...

Activist hedge fund Parvus Asset Management is building a stake in Ozempic-maker Novo Nordisk as the drugmaker hunts for a ...

Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition ...

Investing.com -- Parvus Asset Management, a London-based activist hedge fund, is acquiring a stake in Danish pharmaceutical company Novo Nordisk (NYSE: NVO ), according to The Financial Times. The ...

I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why. Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, ...

The European Medicines Agency warns that Novo Nordisk's Ozempic and Wegovy may, in rare cases, cause NAION—a serious eye condition that can lead to vision loss. The EMA has asked the company to update ...